Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
Sebastian Gensior
About Sebastian Gensior
Sebastian is an expert in understanding healthcare systems around the world and possesses an outstanding ability to estimate how politics can affect biotech and pharmaceutical companies. He started his career at Edelman PR where he serviced pharmaceutical clients and helped them to understand healthcare markets and therapeutic areas. After working at Edelman, he helped Roche to up-skill their global workforce and train the next generation of corporate diplomats. While working with affiliates around the world, he always followed the money in healthcare systems and worked with diverse stakeholders such as health insurance companies and ministries of finance.
After setting up his business, he continues to provide guidance to biotech and pharmaceutical clients that seek a better understanding of healthcare markets and the competitive landscape. Sebastian regularly helps companies to understand therapeutic areas and market segments around the world.
Sebastian graduated from the University of Maastricht (Netherlands) with a B.Sc. in European Public Health. He has a keen eye for statistical shenanigans and knows not to fully trust a companies annual report.